Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anybody see the PR on this from yesterday?
https://www.bizjournals.com/southflorida/news/2020/05/21/reef-partners-with-bioreference-labs.html
Reef Technology and Bioreference partner in Miami to offer Covid testing
Anybody see the PR from our great IR guy on this?
Bio Reference is one of four labs being used in Texas
house.texas.gov/_media/pdf/...
1. COVID-19 Test Result Reporting
We are requesting that all hospitals report data on COVID-19 testing performed in your
Academic/University/Hospital in-house laboratories. If all of your COVID-19 testing is sent
to private labs and performed by the commercial laboratories, you do not need to
report using this spreadsheet.
Commercial laboratories:
A. LabCorp
B. Bio Reference Laboratories
C. Quest Diagnostics
D. Mayo Clinic Laboratories and ARUP Laboratories.
Anybody see the PR from our wonderful IR?
https://www.tapinto.net/towns/jersey-city/sections/government/articles/750k-contract-approved-to-continue-coronavirus-testing-in-jersey-city
JERSEY CITY, NJ - Expecting to get reimbursed through the federal CARES Act, the city council voted earlier this week to approve a $750,000 contract for COVID-19 testing to Bio Reference Laboratories of Elmwood Park.
Of this, $300,000 will be used for antibody testing.
“This is different from the swab test,” said Health Department Director Stacy Flanagan. Although the unit is considered mobile, the state has given approval for a single location at the Marin Avenue fire station in where the tests are to be conducted, Flanagan added.
Sign Up for Jersey City Newsletter
Our newsletter delivers the local news that you can trust.
“We will be working closely with public safety,” she said of the test that requires blood to be drawn. “This is being used to identify potential plasma donors.”
Meanwhile swab tests for COVID-19 will continue in various parts of the city, including senior buildings and parking lots for people who have no doctors or insurance. “We’re doing saliva tests in nursing homes, but we’re getting no support from the state from these,” Flanagan told the councilmembers.
In response to a concern raised by Councilman Daniel Rivera regarding the health of first responders and frontline workers Flanagan offered an assurance that they will indeed continue to have access to testing.
Follow us on Facebook and sign up for TAPinto Jersey City E-News alerts to be the first to read about all things Jersey City!
I read the news and share your optimism.
Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic Platform
Could you please explain to me what this means? Who completed this verification? The company or an outside organization.?
Does this have to go to an FDA like governing body to get approved before usage or can it be implemented immediately.
Any answers would be greatly appreciated. Found this company on another board and I got interested quickly.
I saw the earnings report from the other day and like revenues and fact that expenses were down.
Thanks in advance...
Oh yes,I went to the Website and could not find that answer. It does however look very professional.
DID our brilliant IR guy issue a PR? LOL
Thanks for letting us know about this.
MagnaCare and BioReference Laboratories Bring COVID-19 Antibody Testing to New York Labor Groups
5 minutes ago, 8:00 AM EDT
Via PR Newswire
Stocks mentioned: OPK
Listen
Share
Save
NEW YORK, May 18, 2020 /PRNewswire/ -- MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaboration with BioReference, MagnaCare will offer on-site antibody blood testing to Labor members, delivering valuable information as the city, employers and individuals plan return-to-work strategies.
"As New York's coronavirus outbreak has continued to unfold, our Labor partners have been eager for information and guidance on COVID-19 antibody testing — particularly since skilled trade groups will be among the first to return-to-work and begin re-energizing the local economy," said MagnaCare President Michelle Zettergren. "Antibody testing can support decision making about back-to-work procedures and safety measures for protecting workers and the public. We're proud to bring this service to our clients so they have more knowledge, and hopefully some peace of mind, in this challenging environment."
BioReference Laboratories, which recently worked with New York State and New York City to provide COVID-19 antibody testing, offers a blood test that measures SARS-CoV-2 specific antibody levels to help determine an individual's immune response after COVID-19 infection. Although the presence of antibodies are typically associated with immunity, the scientific community is still working to understand what level of antibodies might be needed for protection from reinfection with COVID-19, and how long that protection might last.
The collaboration will begin with on-site testing for the District Council 9 of the International Union of Painters and Allied Trades (IUPAT) on May 18-20. The on-site testing is available to DC 9 members, who must go online to pre-register and schedule their test. The cost will be fully covered by the union, and results will be emailed directly to members within 72 hours.
"Our goal is to get our members back to work with comfort and confidence," said Joseph Azzopardi, Business Manager and Secretary Treasurer of DC 9. "We're grateful to MagnaCare for providing a convenient testing option so we can all decide how best to move forward in the days and weeks ahead."
Mobile Health
@MobileHealthInc
Mobile Health is now offering the COVID-19 antibody (IgG) test provided by BioReference Laboratories in our NYC clinics.
#mobilehealth #mobilehealthnyc #behindtheline #antibodytest #antibodytesting #covid19testing #returntowork #reentry
10:56 AM · May 6, 2020·Twitter Web App
RapidTestMe announces IgG Antibody Testing for COVID-19 in Union
By RAPIDTESTME
April 30, 2020 at 4:18 PM
Credits: rapidtest.me
RapidTestMe, a private clinic in Union, is now offering testing to detect IgG antibodies against Coronavirus (COVID-19). This blood test from BioReference labs can provide information about a person's immunity to the infection. A positive result indicates that you may have had previous exposure to COVID-19 and your body has developed antibodies - even if you've never had symptoms. Note that experts do not know yet if having antibodies to the virus can protect someone from getting infected again, or how long that protection might last. More data is needed.
BioReference's IgG test not only shows whether you are positive or negative for antibodies, it also indicates the level of antibodies in your system. Other tests only show whether or not you have the antibodies.
It can take 1-3 weeks to make antibodies after symptoms occur. We recommend waiting at least 10 days after testing positive for Coronavirus to have the blood test. Current turnaround time for results is 1 to 2 days. RapidTestMe contacts each person individually with their results.
Sign Up for Union Newsletter
Our newsletter delivers the local news that you can trust.
RapidTestMe offers both Coronavirus testing and antibody testing by appointment only 7 days a week. The Coronavirus test is a viral test (swab of the throat and nose) to determine if you currently have the infection and the antibody blood test indicates if you had a previous infection. RapidTestMe offers both tests either together or individually for $99. Retests are available for $69. Lab costs are not included.
Visit www.rapidtestme.com or call 908-809-3381 for more information.
Editor's Note: This advertorial content is being published by TAPinto.net as a service for its marketing partners. For more information about how to market your business on TAPinto, please email contact@tapinto.net
Breaking News Instant updates and real-time market news.
OPK, PFE 15:13 04/29/20
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $3 price target on Opko Health (OPK) after it said its BioReference Laboratories will start offering SARS-CoV-2 antibody tests. Tenthoff noted that, importantly, Opko and partner Pfizer (PFE) will present Phase III somotrogon data on June 8 at ENDO Online 2020, and submit regulatory filings in the second half of the year. The analyst added that he does not yet know the impact of SARS-CoV-2 testing on BioReference's performance.
OPK PFE
OPK
PFE
OPK Opko Health
$2.32 /
+0.16 (+7.42%)
03/25/20 Piper Sandler
Piper Sandler sees FY20 U.S. sales of Opko's Rayaldee at $52.5M
03/13/20 Piper Sandler
Opko Health coronavirus tests in NY could drive upside, says Piper Sandler
03/10/20 Piper Sandler
Opko Health price target raised to $3.00 from $2.50 at Piper Sandler
03/06/20 Piper Sandler
Coronavirus test could boost Opko services revenue, says Piper Sandler
PR hit TD at 1:35PM
At 2:45 Dow Jones released at article by Wall Street Journal reporter repeating same info.
OPKO Health Unit to Begin Testing MTA Employees for Covid-19 Antibodies
2:45 pm ET April 29, 2020 (Dow Jones) Print
By Maria Armental
OPKO Health Inc.'s BioReference Laboratories will begin testing New York Metropolitan Transportation Authority workers for Covid-19 antibodies under a partnership with New York state.
BioReference will also offer the serological antibody tests nationwide and aims to test 400,000 people a day by mid-May.
"Testing for antibodies is the next logical step to help employers and employees countrywide make decisions as to how to move forward with their jobs and personal lives," said Dr. Jon R. Cohen, BioReference's executive chairman and senior vice president of OPKO Health.
Results, the company noted, signify that antibodies are present, but protective immunity based on these results hasn't been established.
New York Gov. Andrew Cuomo on Wednesday discussed preliminary data from antibody testing of New York City fire department employees, including emergency medical technicians, and New York City police officers and said transit workers' testing would begin today.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
April 29, 2020 14:45 ET (18:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Nice PR by Rite Aid
Where is the OPK IR guy with a PR too?
And why don't they issue a PR about all the
interviews Dr. Cohen from Bio Reference Labs is
giving and provide the links.
Great IR company sitting on their butts!
Interesting Article in WSJ, Taken from another message board
The secret group of scientists and billionaires trying to stop COVID-19. This article is from today's WSJ. Hopefully someone from IPIX is in contact with them.
Article pasted below:
A dozen of America’s top scientists and a collection of billionaires and industry titans say they have the answer to the coronavirus pandemic, and they found a backdoor to deliver their plan to the White House.
The eclectic group is led by a 33-year-old physician-turned-venture capitalist, Tom Cahill, who lives far from the public eye in a one-bedroom rental near Boston’s Fenway Park. He owns just one suit, but he has enough lofty connections to influence government decisions in the war against Covid-19.
These scientists and their backers describe their work as a lockdown-era Manhattan Project, a nod to the World War II group of scientists who helped develop the atomic bomb. This time around, the scientists are marshaling brains and money to distill unorthodox ideas gleaned from around the globe.
They call themselves Scientists to Stop Covid-19, and they include chemical biologists, an immunobiologist, a neurobiologist, a chronobiologist, an oncologist, a gastroenterologist, an epidemiologist and a nuclear scientist. Of the scientists at the center of the project, biologist Michael Rosbash, a 2017 Nobel Prize winner, said, “There’s no question that I’m the least qualified.”
This group, whose work hasn’t been previously reported, has acted as the go-between for pharmaceutical companies looking for a reputable link to Trump administration decision makers. They are working remotely as an ad hoc review board for the flood of research on the coronavirus, weeding out flawed studies before they reach policy makers.
The group has compiled a confidential 17-page report that calls for a number of unorthodox methods against the virus. One big idea is treating patients with powerful drugs previously used against Ebola, with far heftier dosages than have been tried in the past.
The Food and Drug Administration and the Department of Veterans Affairs have already implemented specific recommendations, such as slashing manufacturing regulations and requirements for specific coronavirus drugs.
National Institutes of Health Director Francis Collins told people this month that he agreed with most of the recommendations in the report, according to documents reviewed by The Wall Street Journal and people familiar with the matter. The report was delivered to cabinet members and Vice President Mike Pence, head of the administration’s coronavirus task force.
Dr. Cahill’s primary asset is a young lifetime of connections through his investment firm. They include such billionaires as Peter Thiel, Jim Palotta and Michael Milken—financiers who afforded him the legitimacy to reach officials in the middle of the crisis. Dr. Cahill and his group have frequently advised Nick Ayers, Mr. Pence’s longtime aide, and agency heads through phone calls over the past month.
No one involved with the group stands to gain financially. They say they are motivated by the chance to add their own connections and levelheaded science to a coronavirus battle effort that has, on both state and federal levels, been strained.
“We may fail,” said Stuart Schreiber, a Harvard University chemist and a member of the group. “But if it succeeds, it could change the world.”
Steve Pagliuca, co-owner of the Boston Celtics and the co-chairman of Bain Capital—as well as one of Dr. Cahill’s investors—helped copy edit drafts of their report, and he passed a version to Goldman Sachs Group Inc. Chief Executive David Solomon. Mr. Solomon got it to Treasury Secretary Steven Mnuchin.
The group’s members say they are aware that many of their ideas may not be implemented, and could be ignored altogether by the Trump administration.
This account is based on interviews with scientists, businesspeople, government officials, as well as a review of related documents.
Break out
Only two years ago, Dr. Cahill was studying for his M.D. and PhD. at Duke University, conducting research on rare genetic diseases and wearing $20 Costco slacks. He assumed he would continue the work after graduation.
Instead, he reconnected with a friend who introduced him to a job at his father’s company, the blue-chip investment firm the Raptor Group.
Dr. Cahill got hooked on investing, particularly in life sciences. He reasoned he could make a bigger impact by identifying promising scientists and helping them troubleshoot problems—both scientific and financial—than doing research himself.
After a stint at Raptor, he formed his own fund, Newpath Partners, with $125 million from a small group of wealthy investors, including Silicon Valley stalwart Mr. Thiel and private-equity founders like Mr. Pagliuca. They were attracted to his blunt approach, as well as his interest in tackling intractable problems.
In early March, as the Covid-19 death toll mounted, Dr. Cahill was intrigued and a little depressed with the state of research on the virus. “Science and medicine were the furthest things removed from everything happening,” he said.
His investors peppered him with questions about the virus, and he organized a conference call to share some against-the-grain ideas on how to accelerate drug development and the like. He expected about 20 people.
When Dr. Cahill tried to dial in the meeting, he was rejected because the call had reached capacity. Then his cellphone buzzed from a New York number. It was National Basketball Association Commissioner Adam Silver. He, too, wanted the meeting’s access code. Dr. Cahill later gave him a personal briefing.
Newpath’s deep-pocketed investor base had spread word of the call, and hundreds of people were on the line, most of whom he had never met, including Mr. Milken.
When he finally got on the call, Dr. Cahill took a deep breath and said he had been working with friends to whittle down potential Covid-19 treatments to the most promising. He said he largely dropped his investing work to focus on a hunt for a cure.
After an hour, he hung up and found his email inbox full of ideas and offers to help, including from Mr. Milken’s team. “For the 50 years I’ve been involved in medical research I have never seen collaboration as we have today,” Mr. Milken said.
Dr. Cahill received a handful of notes from advisers to the vice president. They also had been on the call.
The scientist-investor had gained a platform. All he needed was a plan.
Tracing contacts
One of Dr. Cahill’s first calls was to Mr. Schreiber, a founder of several private companies.
Mr. Schreiber looped in a longtime friend, Edward Scolnick, former head of research and development at pharmaceutical giant Merck & Co., where he helped develop 28 new drugs and vaccines. Dr. Scolnick was blunt: A vaccine would take at least 18 months to hit the market under normal circumstances, he told Mr. Schrieber, “if you’re damn lucky.”
Mr. Schreiber responded, “What about six months?”
The team drew up a list of roughly two dozen companies that could benefit from their recommendations and pledged to sell any shares in them immediately. One early member said he couldn’t and was kicked out.
Share Your Thoughts
What is your assessment of the group’s Covid-19 plan?Join the conversation below.
Much of the early work involved divvying up hundreds of scientific papers on the crisis from around the world. They separated promising ideas from dubious ones. Each member blazed through as many as 20 papers a day, around 10 times the pace they would in their day jobs. They gathered to debate via videoconference, text messages—“like a bunch of teenagers,” Mr. Rosbash said—and phone calls.
Personal hygiene went by the wayside. Michael Lin, a Stanford University neurobiologist, began disabling the camera on his phone to protect his vanity. “A couple of days, I’ve had 7 or 8 Zoom meetings, which will itself I’m sure cause some kind of disease,” he joked.
Debates haven’t always been purely science. The group discussed, for instance, whether to suggest that public-health authorities rename the virus “SARS-2,” after the 2003 China animal virus. To them, the name sounded scarier and might get more people to wear face masks. They dropped it.
The team pledged to try to block out politics—not an easy task in the noise and fury of a presidential election year.
Hydroxychloroquine, a malaria drug promoted by the president, was dismissed after the group’s resident expert, Ben Cravatt of Scripps Research in La Jolla, Calif., determined it was a long shot at best. The drug received only a passing mention in the group’s final report.
Hydroxychloroquine pills.
Photo: John Locher/Associated Press
The group also disparaged the idea of using antibody testing to allow people back to work if their results showed they had recovered from the virus. Mr. Cravatt, a chemical biologist, declared it “the worst idea I’ve ever heard.” He said that prior exposure may not prevent people from giving the virus to others, and that overemphasizing antibody testing might tempt some people to intentionally infect themselves to later obtain a clean bill of health.
The group’s initial three phases of recommendations, contained in its report, center on leveraging the scale of the federal government. For instance, buy medicines not yet proven effective as a way to encourage manufacturers to ramp up production without worrying about losing money if the drugs fail. Another is to slash the time required for a clinical review of new drugs to a week from nine months or a year.
The group next needed to get their recommendations to the right people in the Trump administration. For that, Dr. Cahill tapped another well-placed billionaire.
An introduction
Brian Sheth, co-founder of private-equity firm Vista Equity Partners, and a Democrat, had been watching the effort gather steam from his home in Austin, Texas. He was an early investor in Dr. Cahill’s fund and had been on the first call. His expertise was technology, though, not immunology.
He had become friendly with Thomas Hicks Jr., the Dallas businessman and co-chairman of the Republican National Committee. Mr. Sheth introduced Mr. Hicks to Dr. Cahill’s group.
The connection cinched ties between a group of mostly liberal scientists from left-leaning institutions with a Republican stalwart who hunts birds with Donald Trump Jr.
In his first chat with the group, Mr. Hicks said, “I’m not a scientist. Make it clear enough for me, and then tell me where the red tape is.”
A major concern of the scientists was the FDA. The scientists had in their research identified monoclonal antibody drugs that latch onto virus cells as the most promising treatment. But to make the medicine in sufficient quantities, one drugmaker, Regeneron Pharmaceuticals Inc., would have to shift some of its existing manufacturing to Ireland. FDA rules required a monthslong wait for approval.
Mr. Scolnick, who had tussled with bureaucracy during the AIDS epidemic, tried reaching the FDA. The call ended poorly after the bureaucrats told the group they already had the pandemic under control. In a group call afterward, one of the scientists said, of the FDA: “They’re the problem here.”
Why Blood From Coronavirus Survivors Could Be a Lifeline for the Sick
A growing number of hospitals are investigating antibody testing and blood plasma therapy as a way to combat the new coronavirus in sick patients. WSJ’s Daniela Hernandez explains. Photo illustration: Laura Kammermann
Dr. Cahill got in touch with Mr. Ayers. Once the group briefed the vice president’s aide on the bottleneck, Mr. Ayers said he knew who to call. That evening, March 27, Regeneron received a call from the FDA. They had permission, starting immediately, to shift production to Dublin.
“That was proof positive that what we were doing was starting to work,” Mr. Rosbash said.
The group also made inroads with the VA, the largest health care system in the U.S. The scientists pushed the division’s medical staff to allow veterans with Covid-19 to join existing studies in such areas as prostate cancer, to see if already-approved drugs might be effective against the virus. They spoke to the VA’s chief medical officer and secretary about the proposal and learned the initiative was being fast-tracked.
Mr. Pagliuca spoke to Charles Baker, the Republican governor of Massachusetts, on the phone about the report. The governor, Mr. Pagliuca said, planned to adopt elements of the plan.
With much of their scientific proposals under advisement, or already in the process, the group has an eye on the post-Covid-19 world. Mr. Pagliuca pushed the scientists to add a fourth phase to the plan—reopening America.
The ideas include development of a saliva test, and scheduling such test at the end of the workday so results are available by morning. They also have suggested a nationwide smartphone app that requires residents to confirm each day that they don’t have any of 14 symptoms of a cold or fever.
Group members have continued their discussions with administration officials in recent days, hoping their confidential plan turns to action.
“We need the entire nation—government, business and science—to unite to defeat this,” Mr. Pagliuca said.
Write to Rob Copeland at rob.copeland@wsj.com
How much does OPK get for each test kit.
Any numbers on how many tests they are ready to perform and
approximately how many they could be asked to perform?
I see COCP, 10% owned by OPK
issued a PR after hours today....
Cocrystal Pharma Initiates Coronavirus Program, Shares Up 34% After Hours
5:06 pm ET March 6, 2020 (Dow Jones) Print
By Josh Beckerman
Cocrystal Pharma Inc. said it has initiated its coronavirus program and will seek opportunities for collaborations.
The company is "aggressively pursuing the development of novel antiviral compounds."
Shares rose 34% after hours to $1.58.
On Feb. 24, Cocrystal shares more than doubled after the company entered a license agreement with Kansas State University Research Foundation to develop antiviral compounds for norovirus and coronavirus.
Cocrystal, which sold about $11 million of stock in late February, said Friday that its strong financial position will help research and development efforts.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 06, 2020 17:06 ET (22:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Thanks
Thank you for a very thoughtful and thorough response.
Any chance that it could be approved before Aug 7?
TIA
Is today's action related to anything to do with
the Corona Virus. Are they working on any vaccines?
Were they invited to the White House today with Lab Corp and The Quest?
What about Claros?
What about CoCrystal which OPK owns about 10%
Did Canadian Sales begin yet?
BLK, Thanks
Did a google on the Brothers and found that their holdings are in excess of $14.6 Billion. Not too bad. They did make a purchase Friday in excess of $1.7 million in a $3.39 stock. Not sure if I can mention the symbol, but IFRX. Time for some research..
Thanks for getting me to move...
My 2 Cents
I'm sure BB made a very handsome profit (which they are entitled and allowed to do)
I'd like to know what they put that money into and follow them there!
GLTA
Isoray Announces Second Quarter Fiscal 2020 Financial Results
Revenue Increased 16% Year-Over-Year
Gross Profit Increased 45% Year-Over-Year
RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the second quarter fiscal 2020 ended December 31, 2019.
Revenue for the second quarter of fiscal 2020 grew 16% to $2.21 million versus $1.90 million in the prior year comparable period. The company’s core prostate brachytherapy revenue also grew 16% when compared to the fiscal second quarter of 2019. Prostate brachytherapy represented 89% of total revenue for the second quarter of fiscal 2020 compared to 89% in the prior year comparable period. The majority of non-prostate brachytherapy revenue in the quarter was comprised of sales to treat brain cancer, including sales of GammaTile® Therapy.
Gross profit as a percentage of revenues increased to 50.4% for the three months ended December 31, 2019, versus 40.2% in the prior year comparable period. Second quarter gross profit increased 45% to $1.11 million versus $0.77 million in the second quarter of fiscal 2019, largely attributed to increased sales and lower isotope unit costs compared to the prior year comparable period.
Isoray CEO Lori Woods said, “We are pleased to announce another strong quarter of growth and progress. We see continued growth of market share this quarter and we find that particularly rewarding given that we believe topline growth would have been greater had it not been for the timing of the holidays at the end of the quarter. Clearly, our momentum is enduring as preliminary sales for the month of January 2020 increased about 45% versus December 2019 and about 30% versus January 2019. With our growing share of the core prostate market and the increasing use of Cesium Blu™ to treat other hard to treat cancers, we are excited about the prospects for expanding opportunities as we continue to evolve our position as an industry leader and innovator.”
Total operating expenses in the second quarter decreased 8% to $2.01 million compared to $2.19 million in the prior year period. Total research and development expenses decreased 33% versus the prior year comparable period. The decrease in total research and development expenses was primarily the result of decreased protocol expenses, decreased development expenses related to the Blu Build delivery system, and a year-over-year decline in collaborative research expenses related to GammaTile Therapy compared to the prior year comparable period. Sales and marketing expenses decreased 5% versus the prior year comparable period. The decrease in sales and marketing expenses was driven primarily by lower travel and tradeshow related expenses versus the prior year comparable period largely due to a calendar shift of the ASTRO Conference to September 2019. General and administrative expenses decreased 3% versus the prior year comparable period. The decline was primarily the result of a decrease in legal and public company expenses compared to the prior year comparable period.
The net loss for the three months ended December 31, 2019, was $0.90 million or ($0.01) per basic and diluted share versus a net loss of $1.41 million or ($0.02) per basic and diluted share in the comparable prior year period. Basic and diluted per share results are based on weighted average shares outstanding of approximately 67.4 million for the three months ended December 31, 2019, versus 67.3 million in the comparable prior year period.
For the first six months of fiscal 2020 ended December 31, 2019, revenue increased 30% to $4.52 million versus $3.47 million in the prior year comparable period. Prostate brachytherapy represented 89% of total revenue for the first half of fiscal 2020 compared to 89% for the first half of fiscal 2019. Total operating expenses for the first six months of fiscal 2020 decreased 4% to $4.09 million, versus $4.24 million in the prior year comparable period. The net loss for the first half of fiscal 2020 was $1.71 million, or ($0.03) per basic and diluted share, compared to a net loss of $2.92 million, or ($0.04) per basic and diluted share, in the prior year comparable period. Basic and diluted per share results are based on weighted average shares outstanding of approximately 67.4 million for the six months ended December 31, 2019, versus 66.7 million in the comparable prior year period.
Cash, cash equivalents, and certificates of deposit at the end of the second quarter of fiscal 2020 totaled $3.18 million and the company had no debt. Shareholders’ equity at the end of the second quarter of fiscal 2020 totaled $6.14 million.
Conference Call Details
The company will hold an earnings conference call today, February 11, at 4:30 p.m. ET/1:30 p.m. PT to discuss operating results. To listen to the conference call, please dial (844) 602-0380. For callers outside the U.S., please dial (862) 298-0970.
The conference call will be simultaneously webcast and can be accessed at https://www.webcaster4.com/Webcast/Page/2199/33012. The webcast
will be available until May 11, 2020, following the conference call. A replay of the call will also be available by phone and can be accessed by dialing (877) 481-4010 and providing reference number 58363. For callers outside the U.S., please dial (919) 882-2331 and provide reference number 58363. The replay will be available beginning approximately 1 hour after the completion of the live event, ending at 4:30 pm ET on February 18, 2020.
Contacts
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747
About Isoray
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting www.isoray.com. Join us on Facebook and follow us on Twitter.
Safe Harbor Statement
Statements in this news release about Isoray's future expectations, including: the anticipated continued growth in revenues in the quarter ending March 31, 2020, and in fiscal year 2020, lower isotope costs, advantages of our products including Blu Build and the GammaTile Therapy delivery system, whether interest in and use of our Cesium Blu products will increase or continue, whether use of Cesium-131 in non-prostate applications will continue to increase revenue, whether further manufacturing and production process improvements will be completed or will result in lower costs, whether our market presence and growth will continue, the positive industry data fueling renewed interest in brachytherapy, strong patient results, the perception by patients of quality of life outcomes, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, market acceptance and recognition of our rebranded products, our ability to successfully manufacture, market, and sell our Blu Build products and the success of the GammaTile Therapy, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released that support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards, the success of our sales and marketing efforts, changes in reimbursement rates, the procedures and regulatory requirements mandated by the FDA for 510(k) approval and reimbursement codes, changes in laws and regulations applicable to our products, the scheduling of physicians who either delay or do not schedule patients in periods anticipated, the use of competitors' products in lieu of our products, less favorable reimbursement rates than anticipated for each of our products, and other risks detailed from time to time in Isoray's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Great idea
Do you think anyone from the company monitors this board?
Maybe they will take you up on this great idea.
I will keep asking my pharmacist every week if my coverage has improved before I ask my doctor for a prescription. United Health Care Preferred Care Partners $300 a month. I would have to pay full amount.
Thank you for all your information you provide. Much appreciated.
thanks.
Nothing on Yahoo or Inv Vil
What boards are you checking in on?
Any good info, or just speculation?
TIA
Yes, thanks.
I heard that on the interview you provided the link for.
But I am asking about the Gold at Canyon Relief..Any word on when that begins pouring?
Thanks for any help.
So, just wondering if you have seen any updates to their PR from November 2019.
" Relief Canyon Update
On April 3, 2019, the Company's Board gave approval to commence construction of the mining and heap leaching facilities at Relief Canyon following the Pershing Gold Corporation ("Pershing Gold") acquisition. The capital cost to develop Relief Canyon to initial gold pour was estimated to be approximately $28 - $30 million with an additional $8 million in working capital required to achieve sustainable positive cash flow. Construction is proceeding well with preparation of the leach pad complete with approximately 3,200,000 square feet of liner installed. Overliner crushing is complete, and placement of the material is advancing well. The primary crusher and the crushed ore reclaim tunnel are installed. The overland conveyor installation is nearing completion with vulcanizing of the conveyor belt expected in the next two weeks. Initial ore placement is targeted for late November with solution application to begin shortly thereafter. The ADR plant is receiving its final upgrades including the installation of new mercury abatement equipment and a revamped electrowinning area. The Company continues to expect to achieve first gold pour from Relief Canyon in late Q4-2019. "
When should we be seeing those first pours?? Or did it happen already?
TIA
Great Interview
Thanks for the link. Looks like lots of good things to happen.
Good luck to all!
Gold Closed on Friday at $1589.50
So what does that do to your numbers?
TIA
BTIG recommends WKHS $6PT
Workhorse +8.7% as BTIG starts at Buy
Jan. 30, 2020 6:24 PM ET|About: Workhorse Group Inc. (WKHS)|By: Jason Aycock, SA News Editor
Workhorse Group (NASDAQ:WKHS) is up 8.7% on heavy postmarket volume after BTIG opened with a Buy rating on the stock.
It's set a price target at $6, implying 117% upside from today's close.
That's due mainly to benefits from an ongoing shift to electric vehicles, with the company moving toward "solidifying its position as a leading U.S. commercial EV original equipment manufacturer."
It's the only domestic finalist for the USPS Next-Generation Delivery Vehicle program offering an EV solution, it notes.
Recently Seeking Alpha authors have been Bearish on the stock; it has a Quant Rating of Neutral.
Yes and I read what the previous Q/A said
But I am still reading that while they regulate Prescription drugs,they are saying that they sometimes dont see the ads immediately.AND that federal law does not allow FDA to require drug companies submit ads for approval before the ads are used. I think that means that DTC advertising could start immediately. Maybe even like to see an infomercial.
This is what I read....
No. In most cases, federal law does not allow the FDA to require that drug companies submit ads for approval before the ads are used. We see many ads at about the same time the public sees them. Many drug companies voluntarily seek advice from us before they release TV ads. However, if we believe that an ad violates the law, we send a letter to the drug company asking that the ads be stopped right away.
Anyway, I am hoping for the best. We will see.
DTC approval?
Could someone please explain why it takes 6 months to get an approval?
I went to the FDA website and it gives me the impression that is not the case.
Please explain what I am missing. TIA
The following was copied from the website:
Does the FDA review and approve all advertisements for drugs before their release?
No. In most cases, federal law does not allow the FDA to require that drug companies submit ads for approval before the ads are used. We see many ads at about the same time the public sees them. Many drug companies voluntarily seek advice from us before they release TV ads. However, if we believe that an ad violates the law, we send a letter to the drug company asking that the ads be stopped right away.
https://www.fda.gov/drugs/prescription-drug-advertising/prescription-drug-advertising-questions-and-answers
I have not heard back from the companies, but ironically TD Ameritrade, where I have the stock has gotten back to me with the following:
Regarding your restricted shares of Pershing Gold and how that will be dealt with in the merger, short answer to that is, we don't know yet. When two companies merge they'll release information on the existing shares of a company, the two companies have not set the expectation for those restricted shares yet.
At this point I'd recommend reaching out to Pershing Gold's Investor Services department for further information, as if anyone were to have it at this point, they would.
So, I guess we will have to be patient for now.
I have the same question.
So, your message prompted me to email both companies seeking a response.
I would encourage all who have that concern to contact them too.
I wrote to the following three people,hoping one would respond.
Jack Perkins,VP, Investor Relations jperkins@pershinggold.com
Steve Alfers,Pres of Pershing Gold salfers@pershinggold.com
Darren Blasutti Pres of Americas Silver dblasutti@americassilvercorp.com
If I get a response I will post it here and hoping anyone else who finds out does the same.
Good luck to us.
Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split
effective close of business 10/5/17
There is news, but no PR yet...
FDA clears Alliqua BioMedical's SilverSeal wound dressing; shares up 32%
Aug. 28, 2017 12:12 PM ET|About: Alliqua BioMedical, Inc. (ALQA)|By: Douglas W. House, SA News Editor
Thinly traded nano cap Alliqua BioMedical (ALQA +31.9%) jumps on more than an 11x surge in volume on the news that the FDA has granted 510(k) clearance for its SilverSeal Hydrogel wound dressing.
SilverSeal, comprised of 1.5% of almost pure silver, promotes wound healing and delivers broad spectrum antimicrobial activity.
A lot of options awarded today.
Based on showing positive adjusted EBITDA for 2 consecutive quarters. I saw awards to 3 executives of 100,000 shares each.
From the filings:
Represents a restricted stock award that is subject to forfeiture until vested. The award vests fully on the date, if any, the Issuer files financial statements with the SEC on Form 10-K or Form 10-Q that report a positive adjusted EBITDA for the Company for two consecutive fiscal quarters, subject to the Reporting Person's continued service through the applicable vesting date and the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan and that certain restricted stock award agreement by and between the Issuer and the Reporting Person, effective as of June 28, 2017.
After reading the presentation
I had similar thoughts.
And to take it further, 35 sales people covering 50 states and DC,. It's a wonder they are selling anything.
I'd like to know where they are concentrating their sales efforts. Hopefully in the states with largest population, especially elderly areas.
Top ten states by population are California, Texas, Florida, New York,Illinois, Pennsylvania, Ohio, Georgia, N. Carolina, and Michigan.
I sure hope they have done some demographic studies and are concentrating in these states.
Article in Barrons
Celgene Shows Savvy as Gilead Keeps Backsliding -- Barrons.com
7:08 am ET March 16, 2017 (Dow Jones) Print
By Ed Lin
When investors buy shares of Celgene, they are not only getting shares of a savvy company, they are also getting a small biotech exchange-traded fund within it.
It is an ETF rather than mutual fund because the portfolio is more of a passive investment than something actively managed.
Unique among the larger biotechs, Celgene's (ticker: CELG) public holdings total more than $1 billion spread across 12 smaller biotechs. According to S&P Capital IQ, it holds stakes of about 10% or more in Agios Pharmaceuticals (AGIO), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), CRISPR Therapeutics (CRSP), Jounce Therapeutics (JNCE), GlobeImmune (GBIM) and Alliqua BioMedical (ALQA).
In fact, Celgene on March 1 disclosed that it doubled the stake in Alliqua to more than 22%. Alliqua, which has been pummeled in recent years, specializes in advanced wound-care solutions.
Celgene itself has healed nicely from the sector rout last year and has proved to be probably the most resilient. We noted last month that it had already broken out to the upside, in technical-analysis terms.
In terms of competing with peers, it has had a much easier time than Gilead Sciences (ticker: GILD), which we recently opined was "the poster child for big biotech's problems." Gilead's pipeline "has yet to produce a follow-up blockbuster to its hepatitis C treatments, its sales have continued to slide, and it has yet to make an acquisition to add growth back into the mix."
Celgene faces similar headwinds in the sense that it derives most of its revenue from a single product, the blood-cancer drug Revlimid. But Celgene was shrewd enough to reach a settlement in late 2015 that delays a generic threat to Revlimid, and sales haven't slowed meaningfully yet.
Joseph Edelman, founder of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, told us in February, "Celgene keeps chugging along. It has a broad pipeline for cancer and autoimmune diseases; it's in cellular therapy, gene therapy. It has a higher multiple but very stable earnings growth. Gilead is very cheap. If the company can acquire something or give people confidence, there is longer-term value after their cure for hepatitis C."
Celgene indeed keeps chugging along -- a remarkable thing in an industry rife with volatility -- while the confidence of Gilead investors continues to wane. Not even news of a raised dividend or buying a priority review voucher to speed up a Food and Drug Administration review lifted Gilead shares.
Celgene shares suffered in the 2016 biotech slump, but its loss of 3.3% was a gentle landing compared with Gilead's 28% dive. The divergence continues in 2017: Celgene is up 9.6% though Wednesday's close while Gilead has slipped 3.6%.
In a market where the winners keep winning, the investment choices of the winners are certainly of interest.
Celgene paid $2 million for four million additional shares of Alliqua in the latter's private placement of 5.5 million shares at 50 cents a pop. The other major buyer was Alliqua Chairman Jerome Zeldis, who bought 400,000 shares for $200,000. Zeldis had spent nearly 20 years at Celgene, most recently as chief medical officer, before leaving in August to join Sorrento Therapeutics (SRNE) as chief medical officer and president of clinical development.
Celgene now holds the equivalent of more than eight million Alliqua shares, including warrants that are exercisable immediately for about a million shares. It is the largest holder of Alliqua shares, with Celgene admirer Perceptive Advisors in second with 1.9 million shares. Zeldis now holds just under 700,000 Alliqua shares.
Celgene's ties to Alliqua date to November 2013 when Celgene invested $6 million in the latter, and Alliqua received the right to develop and market advanced wound-care products Biovance and Extracellular Matrix.
Don't consider Celgene's latest transaction a clear buy signal for Alliqua, however. Keep in mind that its share price has been slashed 84% since the $3.59 purchase price in Celgene's initial investment. Yet analyst optimism abounds for Alliqua. A consensus of analysts polled by S&P Capital IQ holds a Buy rating.
H.C. Wainwright analyst Swayampakula Ramakanth wrote in November that 2017 could be an inflection point for Alliqua with the planned acquisition of Soluble Systems, a Newport News, Va., wound-care firm. Revenue could double and growth would come from "cross-selling synergies between Alliqua and Soluble Systems sales teams," Ramakanth wrote. He reiterated a Buy rating on Alliqua at the time.
Alas, Alliqua wasn't able to secure the financing to buy Soluble and the deal was called off in late February.
As a big biotech with a sizable public portfolio, Celgene embodies Walt Whitman's declaration, "I am large, I contain multitudes." Even as Celgene chugs along, it has components that exemplify the uncertainties of the sector.
Comments? E-mail us at editors@barrons.com
Follow Ed Lin on Twitter
Like Barron's on Facebook
Follow Barron's on Twitter
(END) Dow Jones Newswires
March 16, 2017 07:08 ET (11:08 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Alliqua BioMedical, Inc. to Acquire Soluble Systems, LLC
Wednesday 5 October 2016
Alliqua BioMedical, Inc. (Nasdaq:ALQA) (“Alliqua” or the “Company”), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that the Company has signed a definitive agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. As part of the transactions, Soluble will contribute and transfer substantially all of its assets into a newly formed subsidiary of Alliqua (“New Alliqua”) and Alliqua will complete a holding company reorganization resulting in New Alliqua becoming the new public parent of Alliqua. New Alliqua will remain publicly traded and change its name to “Alliqua BioMedical, Inc.”
Under the terms of the agreement, Soluble will receive consideration with a total value of approximately $35 million, plus warrants to purchase 4 million shares of New Alliqua common stock at an exercise price of $1.07. The transaction consideration consists of the issuance of approximately 17.6 million shares of Alliqua common stock, valued at $0.89 per share, the assumption of $12.4 million of senior debt, the cash payment due at closing of $5.4 million to retire Soluble’s subordinated debt, $1 million of cash payments by Alliqua to Soluble prior to closing, and $500,000 of other consideration. In addition, Soluble will have the right to appoint one new director to the Company’s board of directors. The transaction is expected to close in the first quarter of 2017 and is subject to certain closing conditions that are described below.
Soluble is a privately held company with 60 employees, formed in 1999 and headquartered in Newport News, Virginia. Soluble markets and distributes a human skin allograft with living cells under the brand name, TheraSkin®. Soluble employs a direct distribution model supported by approximately 40 selling resources that primarily target hospital and wound care customers in outpatient facilities, and generated end-user revenue at an annual run-rate in excess of $18 million during the six months ended June 30, 2016.
“We could not be more excited to announce this transaction, as we believe the combination of Alliqua BioMedical and Soluble Systems will enhance our competitive position with a world-class portfolio of regenerative solutions,” said David Johnson, Chief Executive Officer of Alliqua BioMedical. “I believe this transaction offers the opportunity to combine two strong regenerative technologies companies where the sum of their parts should be greater than the parts themselves.”
Mr. Johnson continued, “The combination of these companies presents many strategic and financial benefits, and I would like to highlight a few that I believe are the most compelling:
"Financially, the benefits from this combination are powerful. The organization’s commercial scale will increase dramatically, as the combined selling infrastructure will nearly double the size of Alliqua’s existing direct salesforce. We expect that broader U.S. direct sales coverage will drive rapid additional market penetration for all Alliqua products with the potential for cross-selling opportunities over time. Post-closing, the combined company’s financial profile should improve with a 2016 annualized revenue base estimated to be between $36 and $38 million, gross margins in excess of 70% and significant operating margin benefits from synergies. Clearly, we believe this financial profile positions us with the requisite scale, a clear path to profitability and improving returns for our stockholders going forward.
"Strategically, this transaction allows Alliqua to enhance both our portfolio of regenerative technologies, and our executive leadership team. Soluble’s TheraSkin is a cryopreserved human skin allograft, composed of living cells, fibroblasts, keratinocytes and a fully developed extracellular matrix. Mist Therapy, Biovance, Interfyl and now TheraSkin, will allow Alliqua Biomedical to offer clinicians a variety of clinically efficacious regenerative technologies for the treatment of challenging wound and tissue repair. Importantly, each of these solutions is supported by a compelling economic value proposition. In addition, I am pleased to announce that Allan Staley, the CEO and Co-Founder of Soluble Systems, and Woody Staub, the President of Soluble Systems, have each accepted management positions in charge of Alliqua’s Reimbursement and Payor Policy group and Alliqua’s new specialized surgical sales force, respectively, effective upon the closing of the transaction. Allan’s expertise in the regenerative technologies space is exceptional, as evidenced by the success to-date of TheraSkin. Similarly, Woody’s experience in the medical device and surgical sectors, with the likes of KCI, Mitek and J&J, should prove immensely valuable as we look forward to rapid market share growth of our regenerative technologies portfolio in the surgical market."
“Soluble Systems is excited to combine its excellent products and passionate employees with Alliqua to grow a great company together,” said Allan Staley, Chief Executive Officer of Soluble Systems.
The combined company’s headquarters will be based in Yardley, Pennsylvania.
About TheraSkin
Soluble’s TheraSkin product is a cryopreserved human skin allograft, composed of living cells, fibroblasts, keratinocytes and a fully developed extracellular matrix. TheraSkin is a U.S. Food and Drug Administration (FDA)-regulated HCT/P product under section 361 of the Public Health Service Act. The product is indicated to be used on all external acute and chronic wounds, including, but not limited to, diabetic foot ulcers, venous leg ulcers, pressure ulcers, burns, radiation injury, necrotizing fasciitis and for use over exposed muscle, tendon, bone and joint capsule. TheraSkin has nationwide Medicare coverage from all eight Medicare Administrative Contractors (MACs) covering all 50 U.S.States, the District of Columbia and Puerto Rico. TheraSkin has coverage for Medicaid in 41 states, the District of Columbia, and Puerto Rico and for TriCare (military) nationally. TheraSkin also has extensive Private Payor coverage, including United Healthcare, Cigna, HCSC, BlueCross/BlueShield (BCBS) of Arizona, New Mexico, South Carolina and Michigan, Carefirst BCBS, and HighMark BCBS. For the six-month period ended June 30, 2016, Soluble’s sales of TheraSkin to end-users was approximately $9.1 million representing growth of approximately 32% over the same period in 2015.
Financing and Other Closing Conditions
The transactions described above are contingent upon Alliqua securing debt or equity financing, or a combination thereof, that results in gross proceeds of at least $45 million, inclusive of any current indebtedness of Soluble or Alliqua that is either assumed, restructured or refinanced by the combined company. To that end, the Company currently expects to restructure the existing senior debt obligations for both Alliqua and Soluble totaling approximately $26.2 million. SWK Holdings Corporation, Soluble’s existing senior lender, has expressed support of this transaction.
The transaction is also subject to various customary closing conditions, including the filing of a registration statement with the Securities and Exchange Commission (the “SEC”), the approval of Alliqua's stockholders and the receipt of certain third party consents, including the senior lenders of both Alliqua and Soluble.
Financial Advisors
Cowen and Company, LLC served as Alliqua’s exclusive financial advisor in connection with this transaction. Canaccord Genuity Inc. served as Soluble’s exclusive financial advisor in connection with this transaction.
Conference Call
Alliqua will host a conference call for analysts and investors tomorrow, October 6, 2016, beginning at 8:00 a.m. ET to discuss the Soluble Systems, LLC transaction. Individuals interested in listening to the conference call may dial 877-545-1409 for domestic callers or 719-325-4785 for international callers and provide access code 5565928. A replay of the call will be available for 14 days and can be accessed by dialing 888-203-1112 for domestic callers or 719-457-0820 for international callers.
The conference call will also be available via a webcast on the "Investors Relations" section of the Company's Web site at: http://ir.alliqua.com/.
About Alliqua BioMedical, Inc.
Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices.
Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl®. The Company also markets its Mist Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
About Soluble Systems, LLC.
Soluble Systems, LLC is the manufacturer and/or distributor of a line of advanced wound care products under the brand names TheraSkin® and TheraGauze®. Soluble’s lead product, TheraSkin®, is a cryopreserved human skin allograft for non-responsive chronic wounds which competes in the fast growing biologic market of advanced wound care. Soluble’s patented SMRT Polymer technology is found in its advanced wound care dressing TheraGauze®, which regulates moisture differentially across a wound bed to aid in wound healing without maceration. Corporate offices are located in Newport News, Virginia. For additional information, please visit: http://www.solublesystems.com/.
Additional Information and Where to Find It
In connection with the proposed transaction, Alliqua will be filing documents with the SEC, including a Registration Statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Alliqua stockholders in connection with the proposed transaction. STOCKHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY STATEMENT/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ALLIQUA, SOLUBLE AND THE PROPOSED TRANSACTION.
Stockholders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov. Stockholders may obtain free copies of the documents filed by Alliqua with the SEC on Alliqua's website at www.alliqua.com under the heading "Investors" and then under the heading “SEC Filings”.
Alliqua and its directors and officers may be deemed participants in the solicitation of proxies from the stockholders of Alliqua in connection with the proposed transaction. Information regarding the special interests, if any, of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of Alliqua is contained its Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC.
This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements under federal securities laws, including, but not limited to, statements related to the anticipated consummation of the transaction between Alliqua and Soluble and the timing and benefits thereof, the anticipated financing and the closing thereof, the combined company’s strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, anticipated product portfolio, development programs and management structure and other statements that are not historical facts. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations of these words or comparable terminology. The reader is cautioned not to place undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
Thanks again.
Was able to see 2 presentations by Menon.
Thanks,
That's New York, but curious if they are presenting in their own back yard in Boston.